Finnish protein engineering company that has developed a high-throughput platform combining wet-lab screening and machine learning to measure and modulate the secretory pathway, accelerating discovery and production of protein biologics.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €5.7 M | Jan, 2026 | seed |
Frequently Asked Questions
Where is Avenue Biosciences located?
Avenue Biosciences is located in Helsinki, Finland.
What industries does Avenue Biosciences operate in?
Avenue Biosciences operates in the following industries: biotechnology, protein engineering, life sciences, machine learning.
When was Avenue Biosciences founded?
Avenue Biosciences was founded on 2026-01-12.
How much total funding has Avenue Biosciences raised?
Avenue Biosciences has raised a total of $5,700,000.
Who are the investors in Avenue Biosciences?
The investors in Avenue Biosciences are: Inventure, University of Helsinki, Dimerent, Balnord, Tesi.
Who are the founders of Avenue Biosciences?
The founders of Avenue Biosciences are: Katja Rosti, TeroPekka Alastalo.
What is the primary mission of Avenue Biosciences?
Avenue Biosciences is dedicated to accelerating the discovery and development of protein biologics. The company aims to ensure that no life-saving therapy remains unrealized due to production barriers by using advanced protein engineering and machine learning.
How does the Avenue Biosciences technology platform improve protein production?
The technology at Avenue Biosciences utilizes a machine-learning-powered platform to screen and optimize thousands of signal peptides. These peptides act as molecular addresses that guide proteins through the cell's secretory pathway, significantly increasing the yield and quality of difficult-to-express proteins.
What types of therapies can be enhanced by Avenue Biosciences?
Avenue Biosciences supports the development of a wide range of protein-based treatments, including monoclonal antibodies, enzymes, mRNA-based vaccines, and other complex biologics that are traditionally challenging to manufacture at scale.
Where is the Avenue Biosciences headquarters and team based?
Avenue Biosciences operates as a transatlantic company with a presence in Helsinki, Finland, and Palo Alto, California. This dual location allows them to collaborate with global partners in the biotechnology and pharmaceutical sectors.
What significant performance benefit does Avenue Biosciences offer for biologics manufacturing?
Avenue Biosciences has demonstrated technology that can provide up to a 500 percent improvement in protein production. By identifying the most efficient secretion pathways, the platform helps lower costs and shortens the time required to bring critical medicines to market.